ALIMTA Plus Gemcitabine as Front-Line Chemotherapy
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A phase II Clinical Trial
Purpose:
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients with Malignant Pleural or Peritoneal Mesothelioma. A phase II Clinical Trial.
Patient Inclusion:
 |
Histologically proven diagnosis of Malignant Pleural or Peritoneal Mesothelioma |
|
2 Weeks post pleurodesis |
|
Radiotherapy MUST BE completed at least 4 weeks |
|
Patient MUST have measurable disease |
|
At least 4 weeks must have elapsed and patients must have recovered from all side effects of Surgery |
Exclusion Criteria:
|
You are excluded from this trial if you have received prior chemotherapy for mesothelioma |
|
You are excluded from this trial if you have brain metastases. |
|
You are excluded from this trial if you have active infection |
|
You are excluded from this trial if you have pregnant or breast feeding. |
|
You are excluded from this trial if you have inability to take folic acid or vitamin B12 administration |
Location/Contact Information:
Mary Hesdorffer, RN, BSN, Clinical Research Nurse
Columbia-Presbyterian Medical Center
Herbert Irving Comprehensive Cancer Center
Columbia University
161 Fort Washington Ave.
New York, NY 10032
Telephone: 212-305-1252
Fax: 212-305-6891
Email: mp317@columbia.edu
